Cigna Group (CI) is back in focus after Evernorth, its health services arm, launched Pharmacy Forward, a $100 million AI-driven specialty pharmacy program, alongside recent upbeat commentary from Bernstein following its review of the business.

Cigna Group’s recent headlines around Pharmacy Forward and upbeat commentary from Bernstein arrive alongside firm share price momentum, with a 7-day share price return of 7.99% and a 90-day share price return of 11.70%. The 5-year total shareholder return of 46.67% points to a steadier longer-run outcome.

If AI in healthcare is catching your eye, this is a useful moment to widen the lens and see which other companies are gaining traction through 40 healthcare AI stocks

After Cigna Group’s sharp recent move and fresh attention on Evernorth, the key question now is whether the shares still offer enough potential reward for the risks involved, or if the easy part of the repricing is already behind you.

Most Popular Narrative: 10.7% Undervalued

The most followed narrative currently points to a fair value of $340.92 for Cigna Group, compared with the recent close at $304.50, putting Evernorth’s latest AI move in a broader context for the stock.

Cigna is capitalizing on the growing demand for specialty pharmacy and care services, particularly as chronic diseases and complex treatments become more prevalent; the double-digit revenue growth in CuraScript and Accredo positions the company to capture an expanding portion of the high-growth $400B+ specialty space, supporting long-term revenue and earnings growth.

Want to see what sits behind that specialty pharmacy story? The narrative ties together measured revenue growth, margin creep, and a future earnings multiple that has to do some heavy lifting. Curious which assumptions carry the most weight in reaching that $340.92 fair value.

Using a discount rate of 7.27%, the narrative discounts Cigna Group’s expected cash generation back to today, then layers in projected revenue growth, modest margin expansion, and a future P/E level that is lower than the broader US Healthcare sector. The result is a fair value that sits meaningfully above the current share price, but still relies on earnings and cash flows tracking close to those expectations rather than breaking sharply higher or lower.

Result: Fair Value of $340.92 (UNDERVALUED)

However, the Cigna Group narrative still has pressure points, including heavy reliance on Evernorth’s PBM model and ongoing regulatory scrutiny of pricing and billing practices.

Next Steps

With mixed sentiment around Cigna Group’s opportunity and risks, this is a good time to move quickly and review the details for yourself through 5 key rewards and 1 important warning sign

Looking for more investment ideas beyond Cigna Group?

If Cigna Group has sharpened your focus, do not stop here. Broaden your watchlist with a few hand picked sets of companies built from clear, data driven criteria.

• Spot potential bargains early by scanning companies that screen well on quality and valuation through screener containing 20 high quality undiscovered gems
• Strengthen your downside protection by zeroing in on companies that combine resilience with modest risk profiles using the 80 resilient stocks with low risk scores
• Target dependable cash generators by reviewing companies that pair higher yielding payouts with sturdier fundamentals in the 8 dividend fortresses

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.